Medivation, Inc. today announced changes to its organizational structure to support anticipated growth as the company prepares to transition from a development stage company to a commercial organization. As part of this transition, chief financial officer (CFO) Patrick Machado will transition to a new role, chief business officer (CBO), in which he will oversee strategic planning, business development, alliance management and intellectual property. In addition, Medivation has recruited a new senior vice president, clinical development, Karen Reeves, M.D., and has made internal promotions creating two new vice president positions. Bryan Selby will be the new vice president, biometrics, and Vandana Date will be the new vice president, intellectual property.
[ad]
“Medivation’s organization is continuing to evolve as we progress our clinical programs and begin to lay the foundation for commercialization of dimebon (latrepirdine*), our late-stage candidate for both Alzheimer’s and Huntington diseases,” said David Hung, M.D., president and chief executive officer of Medivation. “Pat has provided excellent financial leadership as chief financial officer since Medivation was founded in 2003, and we are pleased to have him take on this new strategic role as we enter our next phase of growth and expansion.”
Medivation has commenced a nationwide search for a new CFO. In the interim, Mr. Machado will continue in the role of CFO, in addition to his new position of CBO, until the role is filled.
“We are delighted to also welcome Karen Reeves to our team,” added Dr. Hung. “Karen comes to us from Pfizer where she was vice president, neurosciences global research and development. She participated in the due diligence process for dimebon as a leader on the business development team and served on the joint steering committee for the collaboration. She brings to Medivation years of drug development experience, having held leadership roles at Pfizer in clinical and development programs that resulted in the approval of three marketed drugs, Geodon oral, Geodon IM and Chantix. Under Karen’s leadership as global clinical leader and development team leader, Chantix received priority review from the FDA and was granted the Prix Galien USA Award in 2007, an award considered by many to be the highest accolade in pharmaceutical research and development.”
Dr. Reeves received her B.A. from Yale University and M.D. from the University of Vermont Medical School.
Mr. Selby joined Medivation in October 2007 as a senior director of biometrics, bringing 20 years experience in analyzing clinical trial data in oncology, vascular disease, infectious disease, pain management and auto-immune disease indications. Prior to joining Medivation, he served as a director of statistical programming at ALZA/Johnson & Johnson, Nuvelo, Inc., Corgentech Inc. and InterMune, Inc., and he has performed various statistician and statistical programming functions for companies including Abgenix, Inc., Gilead Sciences, Genentech, Inc., Matrix Pharmaceutical and Monsanto. Mr. Selby earned his B.A. in mathematics from Washburn University and his M.S. in statistics from Kansas State University.
Ms. Date joined Medivation in April 2007 as senior director of intellectual property, bringing 14 years of intellectual property related experience and over five years of experience as a research chemist. Prior to joining Medivation, she served as a director of intellectual property at Threshold Pharmaceuticals, Inc. and a patent attorney at ALZA/Johnson & Johnson and held various patent-related positions at Robins & Associates and Glycomed Inc. Ms. Date received her M.S. in chemistry from both Bombay University and Duke University and a J.D. from Golden Gate University School of Law.
Source: Medivation, Inc.
Popularity: 9% [?]
